TECTA

Across TCGA pan-cancer cohorts, TECTA Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated TECTA data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher TECTA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TECTA expression acts as an unfavorable survival marker, although some lineages such as READ and BLCA show a favorable association.

ESCA, LUSC, and DLBC are the cancer types where TECTA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.168	0.528	.002	21	view →
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
DLBC	OS	Median	All	0.054	0.842	<.001	6	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	6	view →
SARC	OS	Median	All	0.175	0.730	.009	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	IV	0.182	0.654	.021	3	view →
READ	DFS	Median	All	1.000	0.501	.043	2	view →
BLCA	OS	Median	II,III,IV	0.790	0.402	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

TECTA–ESCA (DFS)

Open the ESCA breakdown →